Abstract
A new series of bis-statine based peptidomimetic inhibitors of human beta-secretase (BACE 1) was developed by structure-based modification of the three regions to the initial lead 3: an N-terminus, a central bis-statine core, and a C-terminus. Introduction of a 4-aminomethylbenzoic acid on the C-terminus resulted in a potent BACE 1 inhibitor with an IC50 value of 21 nM. The general requirements for the optimal substrate-enzyme interaction are disclosed herein.
MeSH terms
-
4-Aminobenzoic Acid / chemistry
-
4-Aminobenzoic Acid / pharmacology
-
Amino Acids / chemistry
-
Amino Acids / pharmacology*
-
Amyloid Precursor Protein Secretases
-
Aspartic Acid Endopeptidases / antagonists & inhibitors*
-
Cell Line
-
Endopeptidases
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / pharmacology*
-
Fluorescence Resonance Energy Transfer / methods
-
Humans
-
Inhibitory Concentration 50
-
Models, Molecular
-
Molecular Mimicry
-
Peptides / chemistry
-
Peptides / pharmacology
-
Structure-Activity Relationship
-
Substrate Specificity
-
para-Aminobenzoates*
Substances
-
Amino Acids
-
Enzyme Inhibitors
-
Peptides
-
para-Aminobenzoates
-
4-aminomethylbenzoic acid
-
Amyloid Precursor Protein Secretases
-
Endopeptidases
-
Aspartic Acid Endopeptidases
-
BACE1 protein, human
-
4-Aminobenzoic Acid
-
statine